Tower Research Capital LLC TRC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 76.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,707 shares of the medical research company's stock after acquiring an additional 4,632 shares during the quarter. Tower Research Capital LLC TRC's holdings in IQVIA were worth $2,104,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. World Investment Advisors LLC bought a new position in shares of IQVIA during the third quarter worth about $14,633,000. Arvest Bank Trust Division bought a new position in shares of IQVIA during the 3rd quarter worth approximately $21,079,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of IQVIA in the third quarter valued at approximately $2,310,000. Tidal Investments LLC lifted its position in shares of IQVIA by 9.3% in the third quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company's stock worth $1,417,000 after purchasing an additional 509 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in IQVIA by 1.2% in the third quarter. Franklin Resources Inc. now owns 501,807 shares of the medical research company's stock valued at $117,031,000 after purchasing an additional 6,011 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities analysts have recently commented on IQV shares. Barclays restated an "equal weight" rating and set a $170.00 price objective (down from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Mizuho decreased their price target on IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. StockNews.com downgraded shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. Finally, Robert W. Baird decreased their price objective on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, January 21st. Six analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and an average target price of $241.50.
Read Our Latest Stock Report on IQVIA
IQVIA Stock Performance
NYSE IQV opened at $143.63 on Wednesday. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88. The firm has a 50-day moving average price of $174.25 and a two-hundred day moving average price of $195.42. The company has a market capitalization of $25.32 billion, a P/E ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
